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bstract
To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A poly-
orphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the
reast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192
ontrol patients. While the distribution of individual alleles and genotypes did not differ between patients and controls, there were significant
ifferences in the frequencies of some rare haplotypes and genotype combinations in the MDR1 gene between the two groups.
2007 Elsevier Ltd. All rights reserved.
Disease
a
s
t
A
a
g
t
i
ieywords: MDR1; ABCB1; BCRP; ABCG2; SNP; Haplotype; Genotype;
. Introduction
Acute lymphoblastic leukaemia (ALL) is a clonal dis-
ase of a lymphoblast and the most common malignancy of
ll childhood cancers. It is generally accepted that tumor-
genesis results from complex interplay between inherited
enetic background and specific environmental exposure
1].
The multidrug resistance-1 (MDR1, also referred to as
BCB1) gene belongs to the ATP-binding cassette (ABC)
amily and encodes for membrane transporter P-glycoprotein
P-gp) [2]. P-gp is expressed in several tissues and cells,
∗ Corresponding author at: Heim Pal Pediatric Hospital, P.O. Box 66, H-
958, Budapest, Hungary. Tel.: +36 1 4599 100/1365; fax: +36 1 4599 165.
E-mail addresses: szalai@heimpalkorhaz.hu,
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mong others it is expressed by CD34+ haematopoietic
tem cells [3]. One of the physiological roles of P-gp is
he protection of the organism against toxic xenobiotics.
proportion of xenobiotics transported by P-gp is associ-
ted with mutagen activity [4]. It can be hypothesized that
enetically based differences may result in varying exposure
o environmental carcinogens, with lower activity linked to
ncreased risk of malignancy. Several polymorphisms were
dentified in the MDR1 gene. The most widely studied sin-
le nucleotide polymorphism (SNP) is the C3435T silent
ransition in exon 26, which in some studies was found
o be associated with altered duodenal expression of P-
p and altered substrate specificity and transporter activity
5,6]. The C3435T SNP was found to be in significant link-
ge disequilibrium with other SNPs, including the G2677T
olymorphism in exon 21, resulting in Ala893Ser and also
ssociating with lower P-gp activity [7]. The roles of these
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Table 1
Some clinical and biologic characteristics of ALL patients of this study and of all children from the Hungarian Paediatric Cancer Registry diagnosed with ALL
between 1990 and 2002
Cases in this
study (n = 396)
All cases from the Hungarian Paediatric Cancer Registry
diagnosed with ALL between 1990 and 2002 (n = 776)
Age at diagnosis 1–10 years 316 (79.8) 578 (74.5)
<1 year 5 (1.3) 22 (2.8)
>10 years 75 (18.9) 176 (22.7)
Sex Male 216 (54.5) 442 (57.0)
Female 180 (45.5) 334 (43.0)
Risk group HR 46 (11.6) 124 (16.0)*
MR 252 (63.6) 458 (59.0)*
LR 98 (24.8) 185 (23.8)*
Relapse No 334 (84.8) 622 (80.2)
Yes 60 (15.2) 154 (19.8)
Died No 331 (83.6) 539 (69.5)
Yes 65 (16.4) 237 (30.5)**
Immunophenotype B lineage 291 (84.6) 530 (82.4)***
T lineage 53 (15.4) 113 (17.6)***
Values are given as n (%). Abbreviations: HR: high risk; MR: medium risk; LR: low risk.
* 9 patients were unclassified or unknown regarding risk group.
** P < 0.001.
*** No data available in case of 133 patients.
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oNPs in the risk to ALL are quite controversial. Some stud-
es found an association between 3435 TT genotype and
ncreased susceptibility to childhood ALL, while others did
ot [8,9,10].
The breast cancer resistance protein (BCRP, also known
s ABCG2) is a recently described ABC transporter origi-
ally identified by its ability to confer drug resistance that
s independent of P-gp [11]. The normal function of BCRP
ay be to prevent the accumulation of extra- and intracel-
ular toxins in cells [12]. An early clue to the importance
f BCRP was the fact that its expression in haematopoietic
ells is greater than that of MDR1, suggesting its crucial role
n protecting these cells from toxic xenobiotics [13]. The
wo most frequently identified SNPs in the BCRP gene are
n exon 2 (G34A, resulting in a V12M change) and exon 5
C421A, resulting in a Q141K substitution). Although the
xact functions of these variants have not yet been estab-
ished, some studies indicate that the 421A allele is less
unctional, suggesting a possible role of this variant in the sus-
eptibility to haematological malignancies, including ALL
14].
In this study, we investigated whether the presence of
hese polymorphisms was associated with ALL and whether
ny of these alleles influenced some disease characteristics
nd the outcome of the therapy in the affected individu-
ls. As it is widely accepted, the haplotype structures or
llelic associations can be more predictive than individual
NPs; we also studied the effect of estimated haplotypes
nd genotype combinations on the above-mentioned fea-
ures.
t
F
D
p. Methods
.1. Study population and deﬁnitions
In a retrospective manner, DNA was obtained from 396
hildren (mean age at diagnosis: 6.1 ± 3.9 years) who under-
ent chemotherapy due to acute lymphoblastic leukaemia.
atients were diagnosed with ALL between 1990 and 2002,
ged 1–15 years at diagnosis and treated in ten Hungarian
entres. According to the data of the Hungarian Paedi-
tric Cancer Registry, 776 children were diagnosed ALL
n Hungary in the given time period, therefore our cohort
ontains 51.0% of all patients. See Table 1 to compare
he rate of subpopulations. There is no significant dif-
erence in the distribution of age groups or genders or
LL-immunophenotypes between the whole population and
ur sample-collection. Our sample set contains similar rate of
elapsed patients to what was observed in the whole popula-
ion. However, the rate of died patients is significantly lower
n our study population (P < 0.001). This is because a large
roportion of relapsed patients survive or if die then die many
ears after diagnosis so we could collect samples from many
uch patients. Patients who died during the chemotherapy due
o therapy resistant progressive disease or due to infections
r toxicities of therapy are underrepresented in our sample.
In most cases DNA was extracted from peripheral blood
aken in 2003 and 2004 in haematologic remission (n = 331).
rom patients who died before our sample-collection period,
NA was obtained from bone marrow smears (n = 65, pre-
ared at diagnosis or in remission).
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The 192 control patients (95 male and 97 females; aged
6.8 ± 10.5 years) of the same ethnicity and from the same
eographical region as the patients were randomly selected
rom healthy blood donors. None of the controls have had
hildhood ALL or any other types of cancers previously.
All study subjects belonged to the Hungarian (Caucasian)
opulation. Informed consent was requested from the study
ubjects, or from the parents of patients. The study was
pproved by the Ethics Committee of the Hungarian Medical
esearch Council.
.2. Laboratory methods
Genomic DNA from blood was extracted using the QIAmp
lood DNA Maxi Kit (Qiagen) and from smears with the
ighPure PCR Template Preparation Kit (Roche Diagnos-
ics) according to the manufacturers’ instructions.
The MDR1 C3435T, and G2677T, a genotypes were deter-
ined by a single base extension method based on that
ublished by Gwee et al. [15] with several minor alterations as
escribed earlier [16]. BCRP G34G and C421A genotyping
as performed using the LightCycler (Roche Diagnostics)
llelic discrimination system as described previously [17].
ll genotypes were determined at least twice. Only those
enotypes were accepted, when at least two genotypings gave
he same results.
Genotype findings were verified on two samples for each
enotype by single PCR followed by bidirectional sequenc-
ng using the BigDye v3.1 kit on an ABI310 sequencer.
.3. Statistical methods
Allele frequencies were calculated by allele counting.
ata were analyzed using MedCalc 5.0 and SPSS 11.5 pro-
rams. Hardy-Weinberg equilibrium was tested by using a
2 goodness-of-fit test. χ2 test was used to test for dif-
erences in allele distribution between the groups. Logistic
egression adjusted for age and sex was applied to assess
he effect of the genetic background to dichotomous clinical
haracteristics. Confidence intervals were calculated at the
5% level. Estimated haplotype frequency was calculated by
aploview: http://www.broad.mit.edu/mpg/haploview/ [18].
aplotype-specific ORs were estimated using conditional
ogistic regression to model the log odds of disease as a
unction of the individuals’ haplotype probabilities.
. Results
Table 2 shows the prevalence of the polymorphisms in
atients with ALL and in healthy control subjects. No sig-
ificant differences were observed in genotype or allele
requencies between cases and controls. The genotype dis-
ribution was overall in Hardy-Weinberg equilibrium.
Table 3 shows the estimated haplotype frequencies in
ases and controls in the MDR1 and BCRP genes in respect Ta
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Table 3
Estimated haplotype frequencies in the MDR1 and BCRP genes in the two
populations
Haplotypes ALL children (%) Controls (%) P-values
MDR1 G2677T/A, C3435T
TT 44.4 45.3 0.8
GC 43.2 44.1 0.8
GT 9.4 3.9 0.002a
TC 3.0 6.7 0.006b
BCRP G34A, C421A
GC 86.1 86.6 1.0
GA 10.6 9.4 0.8
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tAC 3.3 4.0 0.9
a OR = 2.5 (1.4–4.4).
b OR = 0.4 (0.2–0.8).
f G2677T/A, C3435T and G34A, C421A polymorphisms,
espectively. While no significant differences were found in
he prevalence of the two predominant haplotypes (TT and
C) in theMDR1gene between cases and controls, there were
ignificant differences in the frequencies of the two rarer hap-
otypes. The GT haplotype was more frequent in cases (9.4%
ersus 3.9%; P = 0.002; odds ratio (OR) = 2.5 (95% confi-
ence interval 1.4–4.4)), while the TC haplotypes were more
revalent in controls (3.0% versus 6.7%; P = 0.006; OR = 0.4
0.2–0.8)). The haplotype distribution did not differ between
he two groups in the BCRP gene. These data indicate that GT
aplotype in the MDR1 gene might associate with increased,
hile TC haplotypes with decreased susceptibility to ALL.
We calculated also the linkage disequilibrium coefficients
D′) between the alleles: MDR1 G2677T and C3435T: 0.6;
2677A and C3435T: 0.04; BCRP G34A and C421A: 0.004
in both controls and cases). As these results show there is a
inkage between the G2677T and C3435T alleles, while there
s no such connection in the other two cases.
Next the distributions of the genotype combinations were
ompared in the two genes in ALL patients and controls.
s can be seen in Table 4A, there are two genotype combi-
ations of the positions 2667 and 3435 in the MDR1 gene
hich occurred more frequently in ALL patients: GT/TT,
8.73% versus 3.17%, in patients and controls, respectively;
= 0.02; OR = 2.88 (1.19–7.11)); and GG/CT (7.41% ver-
us 2.65%; P = 0.04; OR = 2.97 (1.12–7.77)). Furthermore,
enotype combination of TT/CT was more frequent in con-
rols (2.12% versus 7.94%; P = 0.002; OR = 0.26 (0.11–0.61).
he distribution of the genotype combinations in the BCRP
ene did not differ significantly between cases and controls.
Subsequently it was investigated whether these alleles,
aplotypes and genotype combinations influence the clinical
haracteristics of ALL. None of these genetic factors showed
ssociation with age at diagnosis, sex, immunophenotype,
isk group, relapse and leukaemia related death (data not
hown). As Urayama et al. [9] found statistically increased
isk to hyperdiploid ALL (>50 chromosomes) in a small
ubgroups (n = 27) of white non-Hispanic Caucasian ALL
atients with some MDR1 genotypes and a haplotype, we
lso carried out this analysis in our patients. In our patient
s
d
b
crch 32 (2008) 1214–1220 1217
roup there were 78 children with hyperdiploid ALL, but this
hromosomal aberration showed no association with any of
he genotypes or haplotypes. Patients with 2677TA/TT/AA
ad OR = 0.5 (0.3–1.1); those of with 3435TT had OR = 0.7
0.4–1.3), or with TT haplotype had OR = 0.5 (0.3–1.1) for
yperdiploid ALL.
. Discussion
Acute lymphoblastic leukaemia is a multifactorial dis-
ase influenced by genetic and environmental factors. In this
tudy, we investigated whether potentially functional poly-
orphisms in genes coding ABC transporters responsible
or protection of the organisms against environmental car-
inogens might alter the susceptibility to childhood ALL or
nfluence some disease characteristics or the outcome of the
herapy in the affected individuals. In our population, we have
ound that individual polymorphisms in the MDR1 and BCRP
enes do not change the risk for developing the disease, but
he distributions of some haplotypes and genotype combina-
ions in the MDR1 gene differed significantly between ALL
hildren and healthy controls.
It must be noted, however, that this study might have some
imitations. One of them is that our study population is biased
s patients who died before our sample-collection period are
nderrepresented, thus it is possible that the conclusion of this
tudy might be modified if all the patients were involved. Fur-
hermore, although we have matched our patient and control
roups for sex and ethnicity, the two populations differ signif-
cantly in age. But we do not think that this would influence
ur conclusion significantly. Allele and genotype frequencies
n our study in both patients and controls are very similar to
ther published child and adult Caucasian populations [8,9].
n addition, although it is not possible to totally exclude, but
eems very implausible that children and adults with the same
thnicity and from the same environment would differ signif-
cantly just because of their age in haplotype distributions in
enes like MDR1 and BCRP. In addition, none of the controls
ad childhood ALL, thus we think, they were appropriate for
egative controls.
Until now, three studies have been published about the role
f MDR1 polymorphisms in the susceptibility to childhood
LL. Jamroziak and Robak [8] in a study of 113 Caucasian
ases and Hattori et al. [10] in 157 Japanese patients found
n association between 3435 TT genotype and ALL, while
rayama et al. [9] studying 135 non-Hispanic Caucasian
ases did not find such association. Hattori et al. also found an
ssociation when analysed haplotypes involving three poly-
orphisms in the 5′ regulatory region (not involving the
435 alleles) of the MDR1 gene. Urayama et al. also inves-
igated MDR1 haplotypes, but found no association. Our
tudy involved the largest number of Caucasian ALL chil-
ren (n = 396), but was unable to confirm the association
etween MDR1 3435 TT genotype and ALL, but found that
ertain haplotypes and genotype combinations in the MDR1
1218 ´A.F. Semsei et al. / Leukemia Research 32 (2008) 1214–1220
Table 4
Numbers and percentage of some genotype combinations in the MDR1 (A) and BCRP (B) genes
G2677T/A/C3435T ALL children (n = 378) Controls (n = 189) P values
n % n %
(A)
GT/CT 126 33.33 59 31.22 0.7
TT/TT 76 20.11 42 22.22 0.6
GG/CC 66 17.46 42 22.22 0.2
GT/TT 33 8.73 6 3.17 0.02a
GG/CT 28 7.41 5 2.65 0.04b
GT/CC 9 2.38 9 4.76 0.2
TT/CT 8 2.12 15 7.94 0.002c
AG/CC 8 2.12 3 1.59 0.9
AG/CT 7 1.85 5 2.65 0.8
AT/CT 6 1.59 0 0.00 0.2
G34A/C421A ALL children (n = 366) Controls (n = 149) P values
n % n %
(B)
GG/CC 269 73.50% 109 73.15% 1.0
GG/AC 69 18.85% 28 18.79% 1.0
AG/CC 22 6.01% 12 8.05% 0.5
AG/AC 3 0.82% 0 0.00% 0.07
GG/AA 3 0.82% 0 0.00% 0.07
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ta OR = 2.88 (1.19–7.11).
b OR = 2.97 (1.12–7.77).
c OR = 0.26 (0.11–0.61).
ene might influence significantly the risk of ALL in these
hildren. Furthermore, Urayama et al. found statistically sig-
ificant increased risk to hyperdiploid ALL with very high
Rs in carriers of certain MDR1 genotypes and a haplotype.
or example, carrier status of 3435 TT associated with an
lmost 9-fold increased risk to hyperdiploid ALL. In our
tudy with a population almost three times as large as in
hat study (27 versus 78 hyperdiploid ALL cases) we did
ot find such association, even the ORs for the correspond-
ng genotypes were consistently, although not significantly
elow 1.
One possible explanation of these inconsistencies between
he studies can be the relative low numbers of patients inves-
igated in these studies. ALL is a multifactorial disease
nfluenced by several diverse genetic variations. The effects
f these variations are usually modest and detecting them
ould require large number of homogenous patients from
omogenous environment. Although our study involves the
argest number of patients, it still has only 60% power to
etect the difference found in the haplotype analysis. The
ther studies investigated significantly less patients, and this
ould raise the possibility of type 1 error. Unfortunately, it
s very difficult to collect the number of ALL children with
omogenous ethnicity and from similar environment required
or the suitable statistical power to detect such weak genetic
ffects.The other factor that can contribute to the inconsistencies
etween the results is the different environment. For example,
rayama et al. found that although the MDR1 haplotype did
ot influence the susceptibility to the disease when all chil-
c
i
s
xren were considered, but non-carriers of a haplotype exposed
o indoor insecticides had a 3-fold increased risk of ALL
9]. This result shows the significance of the environmental
actors and the gene–environmental interaction in the sus-
eptibility and development of multifactorial diseases, like
LL. It is very much possible that the Californian children
investigated in the other study), and Hungarian children are
xposed to different environmental factors (e.g. among others
ifferent usage of insecticides) thus the gene–environmental
nteraction could result in different phenotype.
Although all studies investigated Caucasian patients, and
he MDR1 allele frequencies were similar in all cases, the
ifferent populations could also differ in genetic background
hich can then contribute to the discrepancies in the results.
Previously, a part of this ALL population was also inves-
igated, whether polymorphisms or haplotypes in the MDR1
ene influenced the side effects of chemotherapy [16,19].
n these studies, it was found that patients with 3435TT
enotype had more frequent encephalopathy episodes and
equired more intravenous antimicrobial therapy during the
hole intensive chemotherapy phase compared to the remain-
ng part of the population. According to these and the present
tudies, the 3435TT genotype does not influence the risk to
LL in our patients, but can influence the side effects of the
herapy.
In spite of decades of extensive research, the physiologi-al role of P-gp remains not fully understood. Several toxins,
ncluding anticancer drugs belong to P-gp substrates which
uggest the involvement of P-gp in protection against toxic
enobiotics [4,20]. In this regard, it can be anticipated that
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enetically based or acquired alterations in P-gp activity may
ead to increased exposure to toxins and by this mechanism
ontribute to increased risk of tumorogenesis. On the other
and, a number of studies provided convincing evidence that
-gp serves several distinct functions in regulation of apop-
otic death, immune response and even stem cells [21,22,23].
hese latter processes can also play some role in carcinogen-
sis.
Several studies investigated the effect of C3435T poly-
orphism on P-gp expression, activity, pharmacokinetic
arameters and susceptibility to different tumors [8].
lthough the results are quite inconsistent, C3435T seems
o be linked with lower P-gp expression, altered substrate
pecifity and higher susceptibility to certain tumors [24,25].
hile C3435T does not lead to an amino acid change, a
ecent study reports altered substrate specificity of certain
DR1 haplotypes containing the 3435T allele because of dif-
erences in folding as a result of translational rate differences
5]. Interestingly, the C3435T polymorphism alone did not
ause altered gene expression, protein function or substrate
pecificity, only as a component of different haplotypes.
According to our results, in Hungarian children the indi-
idual polymorphisms and the most frequent haplotypes of
he MDR1 gene do not influence the susceptibility to ALL,
ut a rare haplotype containing the 3435T allele associates
ith increased risk, while a rare haplotype without this allele
ssociates with decreased risk to ALL. We have also found
hat some rare genotype combinations within the MDR1 gene
ccur more frequently, another one less frequently in ALL
atients than in healthy controls. We believe, that owing to
egative selection, there is a small possibility that frequent
lleles, genotypes and haplotypes can play important role
n disease susceptibility especially in children. But, because
f the several potential different physiological functions of
he P-gp, it is not possible to explain the role of haplotypes
nd genotype associations in such a complex process as
isease susceptibility simply by altered specificity to some
ubstrates. The roles of different MDR1 alleles and haplo-
ypes in childhood ALL must be tested in prospective studies
n large populations considering also the gene–gene and
ene–environmental interactions.
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